Dimerix

Today, on Rare Disease Day 2025, we recognise patients facing limited options. Dimerix is committed to developing DMX-200 for FSGS, bringing hope to those in need. Read more ⬇️ rarediseaseday.org #RareDiseaseDay #FSGS

Our Business Development team is at #BIO2025 in Boston this week, the world’s largest biotech partnering event by @IAmBiotech. Looking forward to productive meetings, fostering partnerships & progress for rare disease innovation. #biotech #FSGS #Dimerix

This week, the Dimerix clinical team is attending two major kidney events: the @ERAkidney Congress in Vienna (world’s 2nd-largest renal conference) and the @PodocyteIPC in Hamburg. Delighted to connect with experts advancing kidney research. #ERA25 #PodocyteConference #FSGS

Dimerix recognises & supports @NephCure’s first-ever #FSGSAwarenessDay, 10 June 2025. #FSGS can affect anyone and often progresses silently. Awareness empowers patients, supports carers & advances research. 🔗 nephcure.org/fsgs-awareness… #Dimerix #biotech #kidneyhealth

🌏 First ACTION3 clinical site now open in Japan Milestone payment of ¥400M (~AU$4.3M) triggered from FUSO as we begin recruiting FSGS patients in Japan. Another step forward in our global Phase 3 journey. 🔗 bit.ly/3SNfWXr #DXB #FSGS #Biotech #ClinicalTrials

Thank you to  @MonsoonComms and @FB_Rice for hosting the #TwilightInvestorBriefing. Delighted to share our progress on DMX-200 for rare kidney disease FSGS—no approved treatment yet, but we’re on our way. ▶️ Replay is now available: youtu.be/e1tbpPFa7LE #DXB #FSGS #Biotech

Missed our investor webinar? Catch the recording now. Dr Nina Webster shares insights on Dimerix’ new licensing deal with @amicusrx1 and what’s next for DMX-200. 🎥 Watch here: youtu.be/95zA09su_pg #Biotech #FSGS #RareDisease #Dimerix

Great news for the #FSGS community!!

We are thrilled to announce the expansion of our pipeline with the U.S. licensing of DMX-200 to bring even more hope to people living with rare diseases. Read more here: ir.amicusrx.com

📢 Dimerix announces US licensing deal for DMX-200 with NASDAQ-listed @amicusrx1 (US$2.2B market cap)—our 4th deal, totalling ~A$1.4B in potential value. Hear directly from CEO Dr Nina Webster in our Investor Webinar today at 11 AM AEST: bit.ly/4jXlfio

✅ Major milestone: FDA confirms proteinuria as an acceptable primary endpoint for full marketing approval of DMX-200 in the US. A significant step forward for Dimerix and #FSGS patients. Learn more: bit.ly/4lQS56k

Dimerix (ASX: DXB) is pleased to be presenting at @ASX CEO Connect today, 15 April 2025 at 10am AEST. Join us to hear the latest on our Phase 3 kidney disease program and more. 🔗 Register now: event.asx.com.au/ceoconnectapri…

Dimerix is delighted to sponsor the @nkf Urinary Protein Workshop in Washington DC this week, supporting expert-led advancements in kidney disease research and treatment. #KidneyHealth #NKF

Dimerix CEO Nina Webster will present at the #HealthInvest Summit in Sydney on 2 April 2025. Hosted by @IR_Department, @MorgansAU & @StockheadAU, the event highlights top health & life sciences firms. Hear about #DXB Phase 3 trials for #FSGS. Register at events.humanitix.com/healthinvest-a…

On #WorldKidneyDay 2025, Dimerix would like to thank FSGS patients & families who inspire us as we work to develop & commercialise DMX-200 for #FSGS, a rare kidney disease. We remain committed to bringing hope to those in need of treatment options. 💙 #AreYourKidneysOK

This #InternationalWomensDay, on March 8th, Dimerix is celebrating the women who build their own path and create positive change for our future generations. We are proud to foster a workplace that supports inclusion and diversity at all levels. #WomenInSTEM #IWD2025

Thank you @Marcus_Today On the Couch show for having us to discuss Dimerix’s Phase 3 trials for #FSGS, global licensing deals & the road ahead. How do Dimerix's innovations reshape renal treatments? 🎧 Tune in now: buzzsprout.com/1852332/episod… #OntheCouch #Biotech #DXB

🚨 The first paediatric patient (12-17) has been recruited for the ACTION3 Phase 3 trial in the UK. A key step towards a potential new treatment for FSGS, a leading cause of kidney failure in children. Learn more: bit.ly/3WoULNl

📢Dimerix partners with FUSO to advance DMX-200 for FSGS in Japan, securing up to ¥10.5B (~AU$107M) in milestone payments + royalties. A major step toward addressing unmet medical needs in kidney disease. ⬇️ Watch our investor webinar: bit.ly/4gGmDVu #Biotech #FSGS